Systematic Characterization of the Clinical Relevance of KPNA4 in Pancreatic Ductal Adenocarcinoma
- 1Department of Gastroenterology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
- 2Shanghai Key Laboratory of Pancreatic Disease, Institute of Pancreatic Disease, Shanghai Jiao Tong University School of Medicine, Shanghai, China
- 3Laboratory of Cancer Genomics and Biology, Department of Urology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
A corrigendum on
Systematic characterization of the clinical relevance of KPNA4 in pancreatic ductal adenocarcinoma
by Bao JP, Xu CL, Li B, Wu ZK, Shen J, Song PL, Peng Q and Hu GY (2022) Front. Oncol. 12:834728. doi: 10.3389/fonc.2022.834728
Error in Figure
In the published article, there was an error in Figures 4F and 4H as published. The group names were erroneously interchanged. The corrected Figures 4F and 4H and its caption “Figure 4. KPNA4 knockdown inhibits proliferation and migration of PDAC cells” appear below.
Figure 4 KPNA4 knockdown inhibits proliferation and migration of PDAC cells. Knockdown efficiency of three siRNA on KPNA4 was detected by qRT-PCR (A). KPNA4 knockdown suppressed cell proliferation of MIA PaCa-2 (B) and PANC-1 cells (C). KPNA4 knockdown inhibited the colony formation of MIA PaCa-2 and PANC-1 cells (D, E). The inhibitory effect of KPNA4 knockdown on MIA PaCa-2 (F) and PANC-1 (H) cell migration was evaluated by wound healing assay at different time points, and the migration index was shown in (G, I). *p < 0.05, **p < 0.01, ***p < 0.001.
We apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: karyopherin subunit alpha 4, pancreatic ductal adenocarcinoma, prognostic biomarker, tumor microenvironment, FAK signaling
Citation: Bao J, Xu C, Li B, Wu Z, Shen J, Song P, Peng Q and Hu G (2023) Corrigendum: Systematic characterization of the clinical relevance of KPNA4 in pancreatic ductal adenocarcinoma. Front. Oncol. 13:1282120. doi: 10.3389/fonc.2023.1282120
Received: 23 August 2023; Accepted: 31 August 2023;
Published: 11 September 2023.
Edited and Reviewed by:
Jitian Li, Henan Luoyang Orthopedic Hospital (Henan Provincial Orthopedic Hospital), ChinaCopyright © 2023 Bao, Xu, Li, Wu, Shen, Song, Peng and Hu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Guoyong Hu, aHVndW95b25nc2hAc2luYS5jb20=
†These authors have contributed equally to this work